ar-a 2

AR-A 2 is a selective 5-HT1B receptor antagonist with high affinity to guinea pig cortex 5-HT1B/1D and recombinant guinea pig 5-HT1B receptors (Ki: 0.24 and 0.47 nM), exhibiting a 10-fold lower affinity to guinea pig 5-HT1D receptor (Ki: 5 nM).

AB928 is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. It has immunomodulatory activity[1].

A2AR/A2BR antagonist 1 (compound 7ai) acts as a dual antagonist to A2AR and A2BR with IC50 values of 11.2 nM and 6.4 nM, respectively. Additionally, A2AR/A2BR antagonist 1 enhances T cell-mediated cancer cell death.

3-Acetoxy-24-hydroxydammara-20,25-diene is a natural product for research related to life sciences. The catalog number is TN2914 and the CAS number is 143519-04-4.

Cibinetide (ARA290) is a nonerythropoietic peptide engineered from erythropoietin,, and used for neurological disease treatment.

Cibinetide (ARA290) acetate is a derivative of EPO, functioning as a specific agonist for the erythropoietin/CD131 heteroreceptor. Cibinetide acetate is utilized in the research of neurological disorders.

GS-9667, a selective and partial agonist of the A(1) adenosine receptor (AR), represents an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA).

Gliquidone (AR-DF 26) is a potent, second-generation sulfonylurea with antihyperglycemic activity, exhibiting greater binding affinity to SUR1 and increased potency compared to first-generation compounds. Additionally, this agent exerts peroxisome proliferator-activated receptor (PPAR) gamma agonistic activity.

Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension.

2'-MeCCPA is a potent and highly selective A1 adenosine receptor (A1AR) agonist with a K-value of 1.8 nM for AR. 2'-MeCCPA inhibits trichostatin-stimulated adenylate cyclase activity with an IC value of 13.1 nM, exhibits analgesic activity, and can be used in the study of HCV.

Verosudil (AR-12286) is a highly potent Rho kinase (ROCK) inhibitor with a Ki of 2 nM and 2 nM against ROCK1 and ROCK2, respectively. AR-12286 mitigates steroid-induced intraocular pressure in mice by decreasing intraocular pressure through enhanced outflow of aqueous humor via the trabecular meshwork.

β3-AR agonist 2 is a potent and selective agonist of β3-adrenergic receptor (β3-AR with an EC50 of 8 nM).

(2S,3S,4'aS,5'R,6'R,8'aR)-3,6'-dihydroxy-2',8'a-dimethyl-6'-(prop-1-en-2-yl)-6-(pyridin-3-yl)-3,4,4',4'a,6',7',8',8'a-octahydrodispiro[furo[3,2-c]pyran-2,1'-naphthalene-5',3''-oxane]-4,6''-dione is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

(2R,4'aR,5'S,6'R,6'aS,10'aR,10'bR)-6'-(acetyloxy)-4'a,6'a,10'b-trimethyl-5''-oxo-decahydro-1'H-dispiro[oxirane-2,7'-naphtho[2,1-b]pyran-3',3''-oxolan]-5'-yl 2-methylpropanoate is a high-purity biochemical reagent suitable for biochemical experiments and drug synthesis research.

AR-9281 (APAU) is a potent and selective inhibitor of soluble epoxide hydrolase (s-EH) potentially for the treatment of hypertension and type 2 diabetes

ar-Turmerone is a natural volatile organic compound extracted from the rhizomes of turmeric (Curcuma longa). ar-Turmerone exhibits oral bioavailability and possesses biological activities such as antitumor, anti-inflammatory, antioxidant, and neuroprotective effects. ar-Turmerone exerts a positive regulatory effect on dendritic cells in mice. Ar-turmerone can induce neural stem cell proliferation both in vitro and in vivo, making it useful for research on neurological disorders. Ar-turmerone induces apoptosis in U937 cells.

O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of Carvedilol, a non-selective β-adrenergic receptor (β-AR) antagonist. This compound inhibits store overload-induced calcium release in HEK293 cells expressing the RyR2 R4496C mutation (IC50= 7.62 µM). Additionally, O-Desmethylcarvedilol slows the increase in heart rate and prevents diastolic pressure reduction induced by Isoproterenol in conscious rabbits (ED50s = 32 and 5 µg/kg).

YT 6-2-PEG3-C2-NH2 is a conjugate of the autophagy-targeting ligand (ATL) targeting p62/SQSTM1 and an AUTOTAC linker. It is used in the synthesis of the AUTOTAC degrader ATC-324 for the androgen receptor (AR). ATC-324 induces the formation of the AR/p62 complex, leading to autophagy-lysosomal degradation of AR. This action reduces nuclear AR levels and downregulates target gene expression of AR and AR-v7, effectively degrading common AR mutants found in prostate cancer (PCa).

BMY 7378 (free base) is a selective antagonist for the α1D adrenergic receptor (α1D-AR). It exhibits a membrane-binding affinity for cloned rat α1D-AR (Ki=2 nM) that is over 100 times stronger than its affinity for cloned rat α1A-AR (Ki=800 nM) or hamster α1B-AR (Ki=600 nM). Additionally, BMY 7378 (free base) acts as a partial agonist at the 5-HT1A receptor.

Antibioticadjuvant 2 (compound 5q) is a potent antibiotic adjuvant that enhances the efficacy of polymyxins and exhibits low toxicity in mammals. The minimum resensitization concentration of Antibioticadjuvant 2 for Escherichia coli AR-0493 is 0.125 μg/mL.

AR Degrader-1 (Compound ML 2-9) is a monovalent degrader of androgen receptors (AR) categorized under molecular glues. In LNCaP prostate cancer cells, it facilitates AR degradation through DCAF16 (E3 ligase) while exhibiting minimal cytotoxicity.

JP-2-196 hydrochloride is a covalent molecular glue degrader that specifically targets RNF126. It facilitates the formation of a ternary complex between RNF126 and target proteins (e.g., BRD4, AR-V7), promoting their ubiquitination and proteasomal degradation. JP-2-196 hydrochloride is being explored for potential applications in cancer research, such as prostate cancer and leukemia.

Compound L-1026, known as Di(5-(methylsulfonyl)-1,3,4-oxadiazol-2-yl)-benzene-amide-PEG4-ester-2,3,5,6-F-Ph, functions as a linker for androgen receptor (AR) RNAi drugs and targeting ligands such as antibodies. This conjugate can inhibit AR gene expression and reduce AR activity. It is applicable in research on spinal and bulbar muscular atrophy (SBMA).

NSD2-IN-6 is a selective inhibitor of NSD2, with an IC50 of 3.8 nM for NSD2 and 274 nM for NSD1. It reduces H3K36me2 levels and reverses cellular plasticity by restoring androgen receptor (AR) signaling pathways. In organoid models, NSD2-IN-6 prompts a transition of cell states from cluster 2 and cluster 3 to cluster 1. In vivo, it exhibits antitumor activity by reversing tumor cell plasticity, inhibiting growth, and promoting apoptosis. NSD2-IN-6 is useful for research in prostate cancer.